Trilafon

Depression, Generalized Anxiety Disorder, Schizophrenia + 8 more
Treatment
12 FDA approvals
20 Active Studies for Trilafon

What is Trilafon

PerphenazineThe Generic name of this drug
Treatment SummaryA medication used to treat mental health disorders, similar to the effects of chlorpromazine.
Perphenazineis the brand name
image of different drug pills on a surface
Trilafon Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Perphenazine
Perphenazine
1987
153

Approved as Treatment by the FDA

Perphenazine, also known as Perphenazine, is approved by the FDA for 12 uses like Depression and moderate Anxiety .
Depression
Used to treat Depression in combination with Amitriptyline
moderate Anxiety
Used to treat moderate Anxiety in combination with Amitriptyline
Schizophrenia
Helps manage Schizophrenia
severe Nausea and vomiting
Anxiety
Used to treat severe Anxiety in combination with Amitriptyline
Generalized Anxiety Disorder
Used to treat Anxiety in combination with Amitriptyline
Mental Depression
Used to treat severe Depressed mood in combination with Amitriptyline
Chronic Physical Illness
Used to treat Chronic Physical Illness in combination with Amitriptyline
Mental Depression
Used to treat moderate Depressed mood in combination with Amitriptyline
Nausea
severe agitation
Used to treat severe agitation in combination with Amitriptyline
moderate Agitation
Used to treat moderate Agitation in combination with Amitriptyline

Effectiveness

How Trilafon Affects PatientsPerphenazine is a powerful medication used to treat psychiatric disorders. It belongs to a class of drugs called phenothiazines, which block the chemical dopamine in the brain. Perphenazine is 10-15 times stronger than other phenothiazine drugs and is just as effective as haloperidol in treating symptoms, but may cause similar early and late side effects.
How Trilafon works in the bodyPerphenazine works by blocking the activity of dopamine receptors, which are responsible for sending signals to the vomiting center in the brain. It also binds to alpha-adrenergic receptors and stops them from sending messages that could lead to nausea and vomiting.

When to interrupt dosage

The prescribed measure of Trilafon is contingent upon the diagnosed ailment, including Generalized Anxiety Disorder, moderate Agitation and Depression. The amount of dosage is contingent upon the administration technique (e.g. Syrup - Oral or Tablet, sugar coated - Oral) outlined in the accompanying table.
Condition
Dosage
Administration
Depression
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
Nausea
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
Anxiety
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
Chronic Physical Illness
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
moderate Anxiety
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
moderate Agitation
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
Mental Depression
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
Mental Depression
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
Generalized Anxiety Disorder
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
Schizophrenia
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
severe agitation
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Warnings

Trilafon Contraindications
Condition
Risk Level
Notes
large dose of CNS depressants
Do Not Combine
Brain Injuries
Do Not Combine
Liver Damage
Do Not Combine
Coma
Do Not Combine
Disease
Do Not Combine
greatly obtunded patients
Do Not Combine
Bone Marrow
Do Not Combine
There are 20 known major drug interactions with Trilafon.
Common Trilafon Drug Interactions
Drug Name
Risk Level
Description
Amisulpride
Major
Perphenazine may increase the antipsychotic activities of Amisulpride.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Perphenazine.
Azelastine
Major
Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Dacomitinib
Major
The metabolism of Dacomitinib can be decreased when combined with Perphenazine.
Deutetrabenazine
Major
The risk or severity of adverse effects can be increased when Perphenazine is combined with Deutetrabenazine.
Trilafon Toxicity & Overdose RiskSigns of an overdose of this drug include confusion and unconsciousness, and children may have seizures. It may take up to 48 hours for symptoms to become noticeable. Tests in rats and mice show that the lowest toxic dose is 318 mg/kg and 64 mg/kg, respectively.
image of a doctor in a lab doing drug, clinical research

Trilafon Novel Uses: Which Conditions Have a Clinical Trial Featuring Trilafon?

At present, 985 active clinical trials are investigating the potential of Trilafon to alleviate moderate Agitation, Anxiety and Nausea.
Condition
Clinical Trials
Trial Phases
Generalized Anxiety Disorder
200 Actively Recruiting
Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3
Schizophrenia
106 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2
moderate Anxiety
0 Actively Recruiting
Nausea
0 Actively Recruiting
Anxiety
0 Actively Recruiting
moderate Agitation
0 Actively Recruiting
Chronic Physical Illness
0 Actively Recruiting
severe agitation
0 Actively Recruiting
Depression
324 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3
Mental Depression
0 Actively Recruiting
Mental Depression
0 Actively Recruiting

Trilafon Reviews: What are patients saying about Trilafon?

5Patient Review
9/25/2009
Trilafon for Mental Disorder with Loss of Normal Personality & Reality
TARDIVE DYSKINESIA
5Patient Review
3/24/2010
Trilafon for Schizophrenia
I've tried a lot of different antipsychotics, and this is the first one that's both effective and doesn't have too many side effects.
5Patient Review
11/26/2010
Trilafon for Schizophrenia
I've tried other medications in the same class as Trilafon, and this one is by far the most effective with the least amount of side effects.
4.7Patient Review
5/7/2010
Trilafon for Mental Disorder with Loss of Normal Personality & Reality
I have bipolar disorder, ADHD, and severe anxiety disorder. I've been on Trilafon for a little while now and it's really helped to stabilize my moods. Much better than any other medication I've tried in the past.
4.7Patient Review
4/10/2010
Trilafon for Mental Disorder with Loss of Normal Personality & Reality
I initially forgot to take this medication, but I was really pleased with how it curbed my appetite. I didn't feel the need to overeat anymore.
4Patient Review
7/14/2010
Trilafon for Schizophrenia
I felt more focused and energetic, with fewer racing thoughts.
4Patient Review
6/2/2009
Trilafon for Schizophrenia
3.7Patient Review
5/14/2013
Trilafon for Schizophrenia
This medication was highly effective at removing my positive symptoms of schizophrenia. However, I developed abnormal mouth and tongue movements as a result. These movements have continued even after going off the medication, which has been since January. Therefore, I would not recommend this drug to anyone.
2.3Patient Review
9/29/2012
Trilafon for Mental Disorder with Loss of Normal Personality & Reality
I was prescribed this medication after being misdiagnosed while in foster care. Even though it's been three years since I stopped taking the medicine, I continue to suffer from a variety of side effects, including sun sensitivity, irregular periods, an irregular heartbeat, sexual problems and eye twitches.
1Patient Review
2/15/2012
Trilafon for Mental Disorder with Loss of Normal Personality & Reality
This treatment made me feel really out of it and not in a good way.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about trilafon

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does perphenazine do to your brain?

"Perphenazine is a type of medication known as a conventional antipsychotic. It works by reducing abnormal excitement in the brain."

Answered by AI

How long does it take for Trilafon to work?

"It may take as much as 4-6 weeks of regular use to see the full benefit of the medication, even though you may notice some effects soon after starting."

Answered by AI

Is Trilafon still available?

"The drug Trilafon is no longer being manufactured in the United States, but similar drugs may still be available. Trilafon was an antipsychotic drug used to treat schizophrenia. It belonged to a class of drugs called phenothiazines."

Answered by AI

What is Trilafon used for?

"Aripiprazole works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain.

Aripiprazole is a medication used to treat certain mental disorders such as schizophrenia and bipolar disorder. This medicine helps the patient to think more clearly and take part in everyday life. It can reduce aggressive behavior and the desire to hurt oneself or others. Aripiprazole works by restoring the balance of certain neurotransmitters in the brain."

Answered by AI

Clinical Trials for Trilafon

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA
The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.
Waitlist Available
Has No Placebo
Cedars-Sinai Medical CenterScott Irwin, MD
Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA
The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.
Waitlist Available
Has No Placebo
University of California San Diego
Have you considered Trilafon clinical trials? We made a collection of clinical trials featuring Trilafon, we think they might fit your search criteria.Go to Trials
Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality for Cancer

18 - 90
All Sexes
Jacksonville, FL
This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and effective way to improve quality of life, reduce anxiety, enhance focus, and promote healthy living for cancer patients undergoing treatment.
Recruiting
Has No Placebo
Mayo Clinic in FloridaJuan C. Cardenas Rosales, MD
Image of Virtual/ No Physical Facility in Palm City, United States.

Akashic Records Sessions for Mental Health

18+
All Sexes
Palm City, FL
The goal of this clinical study is to learn the impact of two Akashic Records sessions on mental health symptoms in adults. We want to see how sessions are linked to stress, anxiety, and depression, and to resilience (ability to bounce back) and feelings of connectedness (to self, community, and humanity). Main questions this study will answer are: After two sessions, what is the impact on stress, anxiety, and depression? After two sessions, what is the impact on resilience and connectedness? How do participants describe their experience of the sessions? After two sessions, what are participants' views of their problems (insight), emotional experiences (impact) and observable behaviors in their daily life? What participants will do: Complete online surveys about their mood at four points: before the first session, before the second session, after the second session, and again 2 months later. Surveys include: DASS-21 (Depression, Anxiety, and Stress Scale) CD-RISC-10 (Connor-Davidson Resilience Scale) WATTS (Connectedness Scale) A short demographic form and satisfaction survey Attend two individual Akashic Records sessions (50-90 minutes each) over private video platform with a licensed clinical social worker (principal investigator) The first 50 participants will also join a one-hour interview with open ended questions with a licensed clinical social worker (co-investigator) about one week after the second session to share their experience in their own words. Who can take part: Adults ages 18 and older who can read and consent in English and who have experienced stress, anxiety, or low mood in the past year. How the research will happen: Sessions are held by secure video call. Participants will also complete private online surveys before, during, and after the sessions. Some participants may be invited to share their experiences in a one-on-one interview. All information is kept private and names are removed before analysis. Risks and benefits: Talking about personal topics may bring up strong emotions. Licensed clinicians conduct sessions, offer support, and provide referrals if needed. Possible benefits include new insights, greater peace or meaning, and improved coping; benefits are not guaranteed. Why this matters: Many people seek spiritual or transpersonal support for emotional concerns. This pilot study will provide early evidence on whether Akashic Records sessions may be a helpful, low-risk option and will guide future research.
Waitlist Available
Has No Placebo
Virtual/ No Physical FacilityCandice S Rasa, LCSW
Have you considered Trilafon clinical trials? We made a collection of clinical trials featuring Trilafon, we think they might fit your search criteria.Go to Trials
Image of Caron Treatment Centers in Wernersville, United States.

Safe and Sound Protocol for Substance Abuse

18 - 75
All Sexes
Wernersville, PA
This study will explore whether the use of the Safe and Sound Protocol (SSP) app is an effective adjunct to treatment as usual (TAU) in individuals with co-occurring substance use disorders and trauma. This study will recruit 129 participants (100 completers) randomized to receive either active or sham SSP in addition to TAU. Participants will utilize the SSP for a minimum of three hours to a maximum of five hours for a total of seven days. Data will be collected at both pre- and post-test. Data to be collected will include measures on affect, anxiety, personality, mindfulness, and posttraumatic stress disorder symptoms. The SSP has shown effectiveness in reducing symptoms of anxiety, depression, and trauma symptoms in pilot studies conducted at other locations. This will be the first study to examine the effectiveness of SSP with individuals with co-occurring SUD and trauma.
Waitlist Available
Device
Caron Treatment CentersErin Deneke, PhD
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA
The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.
Waitlist Available
Has No Placebo
The University of Iowa
Have you considered Trilafon clinical trials? We made a collection of clinical trials featuring Trilafon, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security